This site uses cookies. By continue to use our website you agree to the use of cookies. Find out more, see our Cookie Policy.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
CALL FOR PAPERS Cancer Genomics, Epigenetics, Stem Cell Biology and Microbial Cancer Genomics
CALL FOR PAPERS Advances in Cancer Prevention: Vaccines, Diet and Lifestyle
Nature Genetics Supplement Series

nature genetics
PLOS ONE | T2D-GENES
PLOS One | DISCOVERY
PLOS Genetics | GENETICS of DISEASE
PLOS Genetics | GENETICS of DISEASE
PLOS Genetics | GENETICS of DISEASE

View Article • Google Scholar

15. Nordström T, Adolfsson J, Grönberg H, Eklund M. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. BMC Urology. 2017;17(1):92.
View Article • Google Scholar

16. Karlsson A, Olofsson N, Laure E, Clements M. A parallel microsimulation package for modelling cancer screening policies. In: 2016 IEEE 12th International Conference on e-Science (e-Science); 2016. p. 323–330.

17. Karlsson A, Jauhiainen A, Gulati R, Eklund M, Gronberg H, Etzioni R, et al. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. PLoS ONE. 2019;14(2):e0211918. pmid:30763406
View Article • PubMed/NCBI • Google Scholar

18. Nordström T, Aly M, Clements MS, Weibull CE, Adolfsson J, Grönberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–425.
View Article • Google Scholar

19. Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–967. pmid:22561842
View Article • PubMed/NCBI • Google Scholar

20. och läkemedelsförmånsverket T. Tandvårds-och läkemedelsförmånsverket. Tandvårds-och läkemedelsförmånsverket; 2017.

21. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms. Annals of Internal Medicine. 2013;158(3):145–153.
View Article • Google Scholar

22. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. No. 31 in Statistical Science Series. Oxford: Oxford University Press; 2003.

23. Burström K, Rehnberg C. Hälsorelaterad livskvalitet i Stockholms län 2002. Resultat perutbildningsnivå, födelseland samt sysselsättningsgrupp–en befolkningsundersökning medEQ-5D. Stockholm: Stockholms läns landsting, Centrum för folkhälsa, Enheten för Socialmedicin och; 2006.

24. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595–605. pmid:22894572
View Article • PubMed/NCBI • Google Scholar

25. Socialstyrelsen. Screening för prostatacancer med PSA- prov. Hälsoekonomisk analys. Stockholm: Socialstyrelsen; 2018. Available from: https://www.socialstyrelsen.se/SiteCollectionDocuments/2018-2-13-halsoekonomisk-analys.pdf.

26. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2015.

27. OECD. Purchasing power parities (PPP) (indicator); 2018. Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.

28. Socialstyrelsen. Nationella riktlinjer för vård vid astma och KOL—Stöd för styrning och ledning. Socialstyrelsen; 2018. Available from: https://www.socialstyrelsen.se/publikationer2018/2018-1-36.

29. Karolinska Universitetslaboratoriet. Prostatacancertestet Stockholm-3; 2018. https://www.karolinska.se/KUL/Alla-anvisningar/Anvisning/10245.

30. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009;101:1833–8.
View Article • Google Scholar

31. Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, et al. Budget impact analysis of cancer screening: a methodological review. Applied Health Economics and Health Policy. 2019;17(4):493–511. pmid:31016686
View Article • PubMed/NCBI • Google Scholar

32. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. The New England Journal of Medicine. 2018;378(19):1767–1777. pmid:29552975
View Article • PubMed/NCBI • Google Scholar

33. Drost FJH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. European Urology. 2019.
View Article • Google Scholar

34. Nordström T, Jäderling F, Carlsson S, Aly M, Grönberg H, Eklund M. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies?—protocol of the randomised study STHLM3MRI. BMJ Open. 2019;9(6):e027816.
View Article • Google Scholar

Publications

PLOS Biology
PLOS Medicine
PLOS Computational Biology
PLOS Genetics
PLOS Pathogens
PLOS ONE
PLOS Neglected Tropical Diseases

Home
Blogs
Collections
Give feedback
LOCKSS

Privacy Policy
Terms of Use
Advertise
Media Inquiries
Contact

PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in San Francisco, California, US